Ori Biotech To Use $30M Series A On Cell, Gene Therapy Manufacturing Platform
The London and Woodcliff Lake, New Jersey-based company is developing a platform that closes, automates and standardizes manufacturing for cell and gene therapy developers so they can move their treatments from the pre-clinical process through to scale commercially.
The company has been working with external partners over the past four months doing testing. One partner is already getting good results from testing the platform on its treatment for solid tumors, Ori Biotech’s CEO Jason Foster said in an interview.
Pharma marketing is constantly changing and #AI is helping to reshape how brands connect with their audiences.
Discover Medico Digital top 5 #AI predictions and learn how harnessing the power of AI can boost your marketing strategy. Read more here.
Luscii provides the tools for patient and professional to keep an eye on the recovery while checking vital signs and symptoms to signal deteriorations and intervene timely in case of need.
Read more here.